XML 44 R23.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Collaboration Agreements (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2017
Collaborative Arrangement with Ipsen [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Schedule of Collaborative Revenues Under Collaboration Agreement | During the three and six months ended June 30, 2017 and 2016, collaboration revenues under the Ipsen Collaboration Agreement were as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2017 |  | 2016 |  | 2017 |  | 2016
Amortization of upfront payments and deferred milestone | $ | 4,741 |  |  | $ | 3,592 |  |  | $ | 9,046 |  |  | $ | 4,790 |
Royalty revenue | 219 |  |  | — |  |  | 443 |  |  | — |
Development cost reimbursements | 862 |  |  | — |  |  | 1,199 |  |  | — |
Product supply agreement revenue | 811 |  |  | — |  |  | 1,802 |  |  | — |
Cost of supplied product | (811 | ) |  | — |  |  | (1,802 | ) |  | — |
Royalty payable to GSK on net sales by Ipsen | (328 | ) |  | — |  |  | (664 | ) |  | — |
Collaboration revenues under the Ipsen Collaboration Agreement | $ | 5,494 |  |  | $ | 3,592 |  |  | $ | 10,024 |  |  | $ | 4,790 |
Collaborative Arrangement with Genentech [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Schedule of Collaborative Revenues Under Collaboration Agreement | During the three and six months ended June 30, 2017 and 2016, ex-U.S. royalty revenues and U.S. losses under the Genentech Collaboration Agreement were as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2017 |  | 2016 |  | 2017 |  | 2016
Royalty revenues on ex-U.S. sales of COTELLIC included in Collaboration revenues | $ | 1,367 |  |  | $ | 1,042 |  |  | $ | 3,665 |  |  | $ | 1,172 |
U.S. losses included in Selling, general and administrative expenses (1) | $ | (781 | ) |  | $ | (4,630 | ) |  | $ | (1,407 | ) |  | $ | (11,923 | )
____________________
(1) | A portion of the accrual for losses for three and six months ended June 30, 2016 were reversed in December 2016 when we were relieved of our obligation to pay certain disputed costs as a result of Genentech’s unilaterally change to its approach to the allocation of promotional expenses arising from commercialization of the COTELLIC plus Zelboraf combination therapy.
Collaborative Arrangement with Takeda [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Schedule of Collaborative Revenues Under Collaboration Agreement | During the three and six months ended June 30, 2017, collaboration revenues under the Takeda Collaboration Agreement were as follows (in thousands):
| Three Months Ended June 30, 2017 |  | Six Months Ended June 30, 2017
Amortization of upfront payment | $ | 2,830 |  |  | $ | 4,717 |
Development cost reimbursements | 1,313 |  |  | 2,108 |
Collaboration revenues under the Takeda Collaboration Agreement | $ | 4,143 |  |  | $ | 6,825 |
Collaborative Arrangements with Glaxo Smith Kline [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Schedule of Collaborative Revenues Under Collaboration Agreement | During the three and six months ended June 30, 2017 and 2016, royalties earned by GSK in connection with the sales of COMETRIQ and CABOMETYX were as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2017 |  | 2016 |  | 2017 |  | 2016
Royalties earned by GSK | $ | 2,962 |  |  | $ | 946 |  |  | $ | 5,363 |  |  | $ | 1,218 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |